|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2007-7-6
|
|
pubmed:abstractText |
The alpha-emitter radium-223 ((223)Ra) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone-refractory prostate cancer. We aimed to study mature outcomes from a randomised, multicentre, phase II study of (223)Ra.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1470-2045
|
|
pubmed:author |
pubmed-author:BlomRenéR,
pubmed-author:BolstadBjørgB,
pubmed-author:BrulandOyvind SOS,
pubmed-author:FranzénLarsL,
pubmed-author:GarkavijMichaelM,
pubmed-author:HarmenbergJohanJ,
pubmed-author:JohannessenDag CDC,
pubmed-author:LennernäsBoB,
pubmed-author:NilssonStenS,
pubmed-author:ParkerChristopherC,
pubmed-author:PeterssonUlfU,
pubmed-author:PigottKatharineK,
pubmed-author:SokalMichaelM,
pubmed-author:StrangPeterP,
pubmed-author:TennvallJanJ,
pubmed-author:TyrrellChristopherC,
pubmed-author:YachninJeffreyJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
587-94
|
|
pubmed:meshHeading |
pubmed-meshheading:17544845-Adenocarcinoma,
pubmed-meshheading:17544845-Aged,
pubmed-meshheading:17544845-Aged, 80 and over,
pubmed-meshheading:17544845-Alkaline Phosphatase,
pubmed-meshheading:17544845-Bone Neoplasms,
pubmed-meshheading:17544845-Double-Blind Method,
pubmed-meshheading:17544845-Drug Resistance, Neoplasm,
pubmed-meshheading:17544845-Humans,
pubmed-meshheading:17544845-Male,
pubmed-meshheading:17544845-Middle Aged,
pubmed-meshheading:17544845-Placebos,
pubmed-meshheading:17544845-Prognosis,
pubmed-meshheading:17544845-Prostate-Specific Antigen,
pubmed-meshheading:17544845-Prostatic Neoplasms,
pubmed-meshheading:17544845-Radium,
pubmed-meshheading:17544845-Survival Rate
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
|
|
pubmed:affiliation |
Karolinska Hospital, Stockholm, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase II
|
